Brief: Vaxart Completes Enrollment In Phase 1 Trial For Its Norovirus Oral Pill Vaccine Candidate
30/04/2025 13:25
April 30 (Reuters) - Vaxart Inc VXRT.O: VAXART COMPLETES ENROLLMENT IN PHASE 1 TRIAL FOR ITS NOROVIRUS ORAL PILL VACCINE CANDIDATE VAXART INC - TOPLINE DATA FROM PHASE 1 TRIAL EXPECTED MID-2025 VAXART INC - PLANS PHASE 2 STUDY FOR NOROVIRUS VACCINE IN SECOND HALF 2025 VAXART INC - PHASE 3 TRIAL FOR NOROVIRUS VACCINE COULD BEGIN IN 2026 Source text: ID:nGNXfVBrR Further company coverage: VXRT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vaxart
See all newsBrief: Vaxart Expands Intellectual Property Portfolio With European Patent Protecting Proprietary Norovirus Vaccine Technology
Vaxart Q2 revenue falls on lower government contract income
Brief: Vaxart Q2 Net Income USD -13.494 Million
Brief: Vaxart Enters Cooperation Agreement With Stockholder Group And Announces Board And Corporate Governance Enhancements
Vaxart Q1 revenue more than doubles on government contracts